* Ultragenyx Pharmaceutical Inc reported a quarterly adjusted loss of $1.40​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-2.23. The mean expectation of nineteen analysts for the quarter was for a loss of $1.45 per share. Wall Street expected results to range from $-1.76 to -88 cents per share.

* Revenue rose 42.3% to $139.49 million from a year ago; analysts expected $135.79 million.

* Ultragenyx Pharmaceutical Inc's reported EPS for the quarter was a loss of $1.40​.

* The company reported a quarterly loss of $133.52 million.

* Ultragenyx Pharmaceutical Inc shares had fallen by 8.1% this quarter and gained 6.8% so far this year.

FORECAST CHANGES

* The mean earnings estimate of analysts had risen by about 1% in the last three months.​

* In the last 30 days, three analysts negatively revised earnings estimates

RECOMMENDATIONS

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."

* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Ultragenyx Pharmaceutical Inc is $82.00 This summary was machine generated from LSEG data November 6 at 04:36 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,

MISSED

Sep. 30 2024 -1.45 -1.40 Beat

Jun. 30 2024 -1.69 -1.52 Beat

Mar. 31 2024 -1.73 -2.03 Missed

Dec. 31 2023 -1.62 -1.52 Beat